High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

1. Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.The Pediatric infectious disease journal · 2017
   Trial
2. Benefits and Risks of Statin Therapy in the HIV-Infected Population.Current infectious disease reports · 2018
   Review
3. Statins to improve cardiovascular outcomes in treated HIV infection.Current opinion in infectious diseases · 2016
   Review
4. The role of statins in the setting of HIV infection.Current HIV/AIDS reports · 2015
   Review

Corrections and comments

• Comment on
  High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors.2011

Authors and funding

3 authors at 3 institutions in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as